More frequently than not, compounds which have successfully passed from the pre-clinical setting to the clinic fail in the later stages of drug development.
The data that Biopta provides, at a fraction of the cost of one of these late stage failures, gives an accurate indication of human safety and efficacy data, many years in advance of your compound reaching the clinical setting. This invaluable information allows you to make ‘go’ or ‘no-go’ decisions with certainty based on human data rather than with data from an animal model which might be entirely irrelevant.
Potential investors can also be attracted by the fact that early information on human safety and efficacy is available. Human data vastly contributes to the attractiveness of a compound or development programme.
For more information on the Biopta’s models of human efficacy across the therapeutic areas please click here.